本研究的目的是报告组织学确诊的垂体转移治疗过程。使用Mayo数据浏览器查找具有垂体转移的患者。在2001年至2021年期间确定了21名患者，并回顾性收集了他们的数据。男性最常见的原发癌是肺部（45%），女性最常见的是乳腺癌（33%）。中位年龄为66岁（IQR 56-68岁）。患者表现为头痛（67% [14/21]）、视觉问题（86% [18/21]）、前底垂体功能减退（71% [15/21]）和精氨酸加压素缺乏（38% [8/21]）。在5名患者（24%）的原发癌诊断之前发现了垂体转移。平均肿瘤大小为2.0±0.7cm，90%（19/21）表现为孤立的垂体肿块，无其他颅内转移病灶。常见的放射学特征包括垂体柄增粗（90% [19/21]）、海绵窦受累（71% [15/21]）和鞍脑底部收缩（52% [11/21]）。20名患者进行经蝶窦手术，最常达到亚全切除（76% [16/21]）。14名患者（67%）进行了辅助放疗，15名患者（71%）接受了全身治疗。从手术到放疗开始的中位时间为16天（IQR 11-21天），从手术到全身治疗开始的中位时间为5.0个月（IQR 1.5-14个月）。在治疗过程中，14例中头痛有所改善（57% [8/14]），18例中视觉问题有所改善（61% [11/18]）；5名患者出现新的垂体功能减退。6名患者出现复发，中位无进展生存期为24个月（95% CI 5.4-43个月）。在复发后，1名患有腺样囊性癌的患者进行了两次救治性放疗，4名患者对全身治疗有良好反应。中位总生存期（OS）为25个月（95% CI 7.1-43个月）。神经内分泌性肺肿瘤（261个月）和乳头状甲状腺癌（80个月）患者的平均OS更好，而小细胞肺癌（4个月）和原发未知（5个月）患者的平均OS较差。手术联合或不联合辅助放疗可有效减少肿块，迅速改善视力和头痛症状，并进行明确诊断。即使在局部肿瘤控制失败后，一些患者仍然可以从放疗和/或全身治疗中受益。

The aim of this study was to report the treatment course of histologically confirmed metastases to the pituitary gland (pituitary metastasis).The Mayo data explorer was used to find patients with pituitary metastasis. Twenty-one patients were identified between the years 2001 and 2021, and their data were retrospectively collected.The most common primary cancer origin was lung in men (45%) and breast in women (33%). The median age was 66 years (IQR 56-68 years). Patients presented with headache (67% [14/21]), vision problems (86% [18/21]), anterior hypopituitarism (71% [15/21]), and arginine vasopressin deficiency (38% [8/21]). Pituitary metastases were found before the diagnosis of the primary cancer in 5 patients (24%). The mean ± SD tumor size was 2.0 ± 0.7 cm, and 90% (19/21) presented as a solitary pituitary mass with no other intracranial metastatic lesions. Common radiological features were pituitary stalk thickening (90% [19/21]), cavernous sinus involvement (71% [15/21]), and constriction at the diaphragma sellae (52% [11/21]). Transsphenoidal surgery was performed in 20 patients, and subtotal resection was most frequently attained (76% [16/21]). Fourteen patients (67%) had adjuvant radiation therapy, and 15 patients (71%) were treated with systemic therapy. The median time from surgery to the initiation of radiation therapy was 16 days (IQR 11-21 days), and that from surgery to the initiation of systemic therapy was 5.0 months (IQR 1.5-14 months). During management, headaches improved in 57% (8/14) and vision problems improved in 61% (11/18) of cases; new hypopituitarism occurred in 5 patients. Six patients developed recurrence, and the median progression-free survival was 24 months (95% CI 5.4-43 months). After recurrence, 1 patient with adenoid cystic carcinoma was treated with rescue radiotherapy twice, and 4 patients responded well to systemic therapy. The median overall survival (OS) was 25 months (95% CI 7.1-43 months). The mean OS was better in patients with neuroendocrine lung tumor (261 months) and papillary thyroid carcinoma (80 months) and worse in patients with small cell lung cancer (4 months) and unknown origin (5 months).Surgery with or without adjuvant radiotherapy is effective for mass reduction, rapid symptomatic improvement of vision and headaches, and definitive diagnosis. Even after local tumor control failure, some patients still benefit from radiation and/or systemic therapy.